Loss of Stromal Caveolin-1 Expression:A Novel Tumor Microenvironment Biomarker That Can Predict Poor Clinical Outcomes for Pancreatic Cancer

SHAN Tao,ZHENG Bo,CHEN Xi,WU Tao,BAI Yu-hua,JI Er-Ii,WANG Ji-xin

DOI: https://doi.org/10.3969/j.issn.1671-6264.2015.04.012

2015-01-01

Abstract:Objective:Cancer development and progression is not only associated with the tumor cell proliferation but also depends on the interaction between tumor cells and the stromal microenvironment.A new understanding of the role of the tumor microenvironment suggests that the loss of stromal caveolin-1 ( Cav-1 ) as a key regulator may become a potential therapy target.This study aims to elucidate whether stromal Cav-1 expression in pancreatic cancer can be a strong prognosis biomarker.Methods: Tissue samples from 45 pancreatic cancer patients were studied.Stromal Cav-1 expression was measured from pancreatic cancer, paraneoplastic, and normal tissue by using immunohistochemistry.We analyzed the correlation of stromal Cav-1 expression with clinicopathologic features and prognostic.Results:Specimens from six patients(13.3%) showed high levels of stromal Cav-1 staining, those from eight patients ( 17.8%) showed a lower, intermediate level of staining, whereas those from 31 patients (68.9%) showed an absence of staining.Stromal Cav-1 loss was associated with TNM stage( P=0.018) , lymph node metastasis(P=0.014), distant metastasis(P=0.027).The relationships of age, sex, histological grade, and tumor size with stromal Cav-1 expression were not significant ( P>0.05 ) .Conclusion: The loss of stromal Cav-1 in pancreatic cancer is an independent prognostic indicator, thus suggesting that stromal Cav-1 may be an effective therapeutic target for patients with pancreatic cancer.